Glaukos Secures Permanent J-Code for Keratoconus Treatment
Event summary
- Glaukos has received a permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J2789) for its Epioxa™ treatment.
- The J-code, effective July 1, 2026, is intended to streamline reimbursement for Epioxa by U.S. payers.
- Epioxa is a photoenhancer used in epithelium-on corneal collagen cross-linking for keratoconus treatment.
- The treatment offers an incision-free alternative to traditional cross-linking procedures.
The big picture
The assignment of a permanent J-code is a significant step for Glaukos, addressing a key hurdle to broader commercial adoption of Epioxa. Keratoconus, a relatively rare but serious condition, represents a niche market with unmet needs, and streamlined reimbursement is crucial for expanding access to innovative therapies. This development underscores the ongoing importance of navigating the complex U.S. healthcare reimbursement system for medical device and pharmaceutical companies.
What we're watching
- Adoption Rate
- The actual speed of adoption by providers and the resulting impact on Epioxa sales will depend on the ease of implementation and perceived value of the new J-code.
- Payer Response
- How consistently commercial payers follow CMS’s lead in coverage and reimbursement will determine the long-term benefit to Glaukos’s revenue stream.
- Competitive Landscape
- The success of Epioxa’s adoption may accelerate innovation and competition within the corneal cross-linking market, potentially impacting Glaukos’s pricing power.
Related topics